 FREMONT, Calif., July 27, 2021 GLOBE NEWSWIRE -- Cytek Biosciences, Inc. Cytek Biosciences or Cytek Nasdaq: CTKB, a leading cell analysis solutions company, announced today the closing of its initial public offering of an aggregate of 14,564,635 shares of its common stock at a price to the public of 17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were 200 million. The offering consisted of 11,764,706 shares issued and sold by Cytek, and 2,799,929 shares sold by the selling stockholders named in the prospectus. Cytek did not receive any proceeds from the sale of shares by the selling stockholders. In addition, Cytek has granted the underwriters a 30-day option to purchase up to an additional 2,184,695 shares of common stock solely to cover over-allotments, if any, at the initial public offering price, less underwriting discounts and commissions. Cyteks shares of common stock are listed for trading on The Nasdaq Global Select Market under the ticker symbol CTKB. 